Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Clascoterone vs Tazarotene: Tazarotene has the stronger overall evidence (7.5 vs 7/10); they're alternatives for clearer skin (acne) — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Tazarotene wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Clascoterone and Tazarotene have evidence — compare verdict strength side-by-side.
Apply a thin layer of clascoterone 1% cream to the affected area twice daily, morning and evening, on clean dry skin
Morning and evening
Clascoterone 1% cream
Apply a thin layer once daily in the evening to clean, dry skin. Strengths: 0.045% lotion, 0.05% and 0.1% cream/gel, 0.1% foam. Start every other night if irritation appears.
evening
Tazarotene 0.045% lotion
immediate
12 weeks
12 weeks
1-4 weeks
immediate
12 weeks
24 weeks
1-4 weeks
Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials
JAMA Dermatol (2020) · Rct · n=1440
The pivotal registration trials: two identical phase 3 studies, 1440 patients randomised, conducted November 2015 to April 2018.
Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
J Drugs Dermatol (2023) · Rct · n=1421
709 patients received clascoterone and 712 received vehicle in the pooled ≥12-year population.
Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials
Dermatol Ther (2021) · Meta analysis · n=2457
Five trials, 2457 patients (1357 clascoterone, 1100 placebo), overall low risk of bias.
Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials
J Drugs Dermatol (2020) · Rct · n=1614
The two identical phase 3 registration trials for the 0.045% lotion — 1614 subjects aged 9 and older.
New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis
J Drugs Dermatol (2020) · Rct · n=684
A pooled paediatric SUBGROUP analysis of the two phase 3 trials, not a separate trial: 136 patients aged 10-13 and 548 aged 14-17.
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial
Arch Dermatol (2002) · Rct · n=563
The long photodamage trial: 24 weeks double-blind, then a 28-week open-label extension — 12 months in total, 563 patients.
Tazarotene has a higher evidence score (7.5/10 vs 7/10) and wins in 2 of 3 categories.
For clearer skin (acne), Clascoterone has a higher relevance score (92 vs 88).
No known interactions between Clascoterone and Tazarotene have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.